CompletedPhase 1

Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes

United States21 participantsStarted 2010-09

Plain-language summary

The study tests the notion that patients suffering from certain types of congenital myasthenic syndromes are benefitted by the use of Albuterol at doses used in clinical practice.

Who can participate

Age range2 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of congenital myasthenic syndrome substantiated by typical clinical history, seronegativity to AChR and MuSK, and evidence of a decremental EMG response. Exclusion Criteria: * Uncontrolled hypertension, arrhythmias, or other significant cardiac disease.

What they're measuring

Name: Efficacy of albuterol in the treatment of congenital myasthenic syndromes

Timeframe: 3 years

Trial details

NCT IDNCT01203592

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-08

View on ClinicalTrials.gov More Congenital Myasthenic Syndrome trials